Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer

BACKGROUND. Human epidermal growth factor receptor (HER)-2 testing in patients with operable breast cancer is aimed at identifying candidates for adjuvant anti–HER-2 treatment. However, commonly defined “HER-2(−)” tumors express variable levels of the HER-2 protein, which can influence prognosis. We...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Rossi, Valentina, Sarotto, Ivana, Maggiorotto, Furio, Berchialla, Paola, Kubatzki, Franziska, Tomasi, Nicoletta, Redana, Stefania, Martinello, Rossella, Valabrega, Giorgio, Aglietta, Massimo, Ponzone, Riccardo, Montemurro, Filippo
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2012
Témata:
Breast Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3500362/
https://ncbi.nlm.nih.gov/pubmed/22951668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0194
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky